Loading...
•
Dec 31, 2019
Travere Q4 2019 Earnings Report
Retrophin reported results for the fourth quarter and full year 2019, with pivotal studies advancing and full-year net product sales reaching $175 million.
Key Takeaways
Retrophin reported fourth-quarter net product sales of $46.7 million, compared to $43.8 million for the same period in 2018. The company's focus on advancing sparsentan in FSGS and IgA nephropathy pivotal studies is progressing, with topline data expected in the coming years.
Phase 3 DUPLEX study of sparsentan in FSGS nears enrollment completion, with topline data expected in the first half of 2021.
Phase 3 PROTECT study remains on track to reach enrollment of 280 patients with IgAN by early 2021, with topline data expected in the first half of 2022.
Fourth-quarter net product sales reached $46.7 million, compared to $43.8 million in the same period of 2018.
Cash, cash equivalents, and marketable securities totaled $398.5 million as of December 31, 2019.
Revenue by Segment
Forward Guidance
In 2020, the company anticipates mid-single-digit percentage growth in net product sales compared to 2019.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...